EpiVario Secures Exclusive Worldwide License

EpiVario Secures Exclusive Worldwide License for Novel Technologies and Drugs for Memory-Related Psychiatric Diseases from University of Pennsylvania

Company acquires full rights, in all fields, for novel drug to treat memory-related psychiatric disorders, such as post-traumatic stress disorder (PTSD)

Read More

EpiVario Raises $445K in Seed Funding

EpiVario Raises $445K in Seed Funding to Develop a Novel Drug to Treat Post-Traumatic Stress Disorder (PTSD) at the Source of the Disease

Company is developing novel drug to treat memory-related psychiatric disorders by targeting a non-essential gene – acetyl CoA synthetase (ACSS2)

Read More